These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34001209)

  • 1. A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks.
    Yuan C; Chen H; Tu S; Huang HY; Pan Y; Gui X; Kuang M; Shen X; Zheng Q; Zhang Y; Cheng C; Hong H; Tao X; Peng Y; Yao X; Meng F; Ji H; Shao Z; Sun Y
    Genome Biol; 2021 May; 22(1):156. PubMed ID: 34001209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
    Sheng T; Ho SWT; Ooi WF; Xu C; Xing M; Padmanabhan N; Huang KK; Ma L; Ray M; Guo YA; Sim NL; Anene-Nzelu CG; Chang MM; Razavi-Mohseni M; Beer MA; Foo RSY; Sundar R; Chan YH; Tan ALK; Ong X; Skanderup AJ; White KP; Jha S; Tan P
    Genome Med; 2021 Oct; 13(1):158. PubMed ID: 34635154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hyper-activation of transcriptional enhancers in breast cancer.
    Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
    Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis.
    Cao P; Li F; Xiao Y; Hu S; Kong K; Han P; Yue J; Deng Y; Zhao Z; Wu D; Zhang L; Zhao B
    Dis Markers; 2022; 2022():5118444. PubMed ID: 35237359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
    Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
    J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-YA Overexpression in Lung Cancer: LUAD.
    Bezzecchi E; Ronzio M; Semeghini V; Andrioletti V; Mantovani R; Dolfini D
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32075093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma.
    Jin J; Liu C; Yu S; Cai L; Sitrakiniaina A; Gu R; Li W; Wu F; Xue X
    Aging (Albany NY); 2021 Jun; 13(12):16144-16164. PubMed ID: 34115610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
    Luo S; Luo Y; Wang Z; Yin H; Wu Q; Du X; Xie X
    Cancer Lett; 2024 May; 589():216811. PubMed ID: 38490328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
    Lv Z; Lei T
    BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
    Kaneko S; Takasawa K; Asada K; Shiraishi K; Ikawa N; Machino H; Shinkai N; Matsuda M; Masuda M; Adachi S; Takahashi S; Kobayashi K; Kouno N; Bolatkan A; Komatsu M; Yamada M; Miyake M; Watanabe H; Tateishi A; Mizuno T; Okubo Y; Mukai M; Yoshida T; Yoshida Y; Horinouchi H; Watanabe SI; Ohe Y; Yatabe Y; Saloura V; Kohno T; Hamamoto R
    Mol Cancer; 2024 Jun; 23(1):126. PubMed ID: 38862995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma.
    Mullen DJ; Yan C; Kang DS; Zhou B; Borok Z; Marconett CN; Farnham PJ; Offringa IA; Rhie SK
    PLoS Genet; 2020 Sep; 16(9):e1009023. PubMed ID: 32925947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
    Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
    Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis.
    Pan X; Ji P; Deng X; Chen L; Wang W; Li Z
    Gene; 2022 Feb; 810():146054. PubMed ID: 34737001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel lncRNA, LUADT1, promotes lung adenocarcinoma proliferation via the epigenetic suppression of p27.
    Qiu M; Xu Y; Wang J; Zhang E; Sun M; Zheng Y; Li M; Xia W; Feng D; Yin R; Xu L
    Cell Death Dis; 2015 Aug; 6(8):e1858. PubMed ID: 26291312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma.
    Jiang X; Qin N; Hua T; Wei X; Li Y; Chen C; Gong L; Liu S; Wang C; Yin R; Jiang Y; Dai J; Xu L; Shen H; Ma H
    Mol Carcinog; 2022 Aug; 61(8):776-786. PubMed ID: 35596703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.